Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: A microdialysis study

Journal of Sexual Medicine

Volumn 7, Issue 5, 2010, Pages 1757-1767

  Allers, Kelly A ^a   Dremencov, Eliyahu ^b   Ceci, Angelo ^a   Flik, Gunnar ^a   Ferger, Boris ^a   Cremers, Thomas I F H ^b   Ittrich, Carina ^a   Sommer, Bernd ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Dopamine; Flibanserin; Medial Prefrontal Cortex; Norepinephrine; Nucleus Accumbens; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; FLIBANSERIN; GLUTAMIC ACID; MONOAMINE; NORADRENALIN; SEROTONIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BENZIMIDAZOLE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 2 AGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG EFFICACY; FEMALE; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOTHALAMUS; MECHANICAL PROBE; MICRODIALYSIS; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SEROTONINERGIC SYSTEM; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; STEREOTACTIC PROCEDURE; WISTAR RAT; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PREOPTIC AREA;

ANIMALS; BENZIMIDAZOLES; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICRODIALYSIS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PREOPTIC AREA; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 77953201212     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01763.x     Document Type: Article

References (36)

1. Pfaus JG. Pathways of sexual desire. J Sex Med 2009, 6:1506-33.
2. Fields HL, Hjelmstad GO, Margolis EB, Nicola SM. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu Rev Neurosci 2007, 30:289-316.
3. Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008, 58:1-17.
4. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, 4th, edition. Text Revision, Washington, DC
5. Kaplan HI, Sadock BJ. Comprehensive textbook of psychiatry 1995, 6th, edition, Baltimore, MD, Lippincott Williams and Wilkins
6. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008, 112:970-8.
7. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev 2002, 8:117-42.
8. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Patel P, Mikl J, Sand M, Pyke R. Efficacy of continued flibanserin treatment in premenopausal women with hypoactive sexual desire disorder: Results from the ROSE study. J Sex Med 2009, 6:114. Ref Type: Abstract
9. Jolly E, Clayton AH, Thorp J, Kimura T, Sand M, Pyke R. Efficacy of flibanserin 100 mg qhs as a potential treatment for hypoactive sexual desire disorder in North American premenopausal women. J Sex Med 2009, 6(5):465. suppl, Ref Type: Abstract
10. Clayton A, Jayne C, Jacobs M, Kimura T, Pyke R, Lewis-D'Agostino D. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in North American premenopausal women: Results from the DAHLIA trial. J Sex Med 2009, 6(5):408. suppl, Ref Type: Abstract
11. Jolly E, Clayton A, Thorp J, Nappi R, Kimura T, Hanes V, Pyke R. Safety and tolerability of flibanserin in premenopausal women with hypoactive sexual desire disorder. J Sex Med 2009, 6(5):409. suppl, Ref Type: Abstract
12. Jolly E, DeRogatis L, Komer L, Katz M, Moreau M'G, Kimura T, Pyke R. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in North American premenopausal women: Results from the VIOLET trial. J Sex Med 2009, 6(5):466. suppl, Ref Type: Abstract
13. Aubert Y, Converse A, Sommer B, Allers K, Abbott D. Comparison of flibanserin with the 5-HT1A agonist (+)-8-OH-DPAT in affecting interactions between male-female marmoset pairs. J Sex Med 2009, 6(5):422. suppl, Ref Type: Abstract
14. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: Role of 5-HT(1A) receptors. Br J Pharmacol 2003, 139:1281-8.
15. Carlezon WA, Thomas MJ. Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis. Neuropharmacology 2009, 56(1):122-32. suppl
16. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000, 57:1012-30.
17. Paredes RG. Medial preoptic area/anterior hypothalamus and sexual motivation. Scand J Psychol 2003, 44:203-12.
18. Spinella M. The role of prefrontal systems in sexual behavior. Int J Neurosci 2007, 117:369-85.
19. Paxinos G, Watson C. The rat brain in stereotaxic coordinates 2007, 6th, edition, Amsterdam, Academic Press
20. Scandroglio A, Monferini E, Borsini F. Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors. Pharmacol Res 2001, 43:179-83.
21. Artigas F, Romero L, de MC, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996, 19:378-83.
22. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995, 115:1064-70.
23. Romero L, Bel N, Artigas F, de MC, Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996, 15:349-60.
24. Rueter LE, de MC, Blier P. In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain. Synapse 1998, 29:392-405.
25. Rueter LE, Blier P. Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. Br J Pharmacol 1999, 126:627-38.
26. Kreiss DS, Lucki I. Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT. Neuropharmacology 1992, 31:1073-6.
27. Borsini F, Ceci A, Bietti G, Donetti A. BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 1995, 352:283-90.
28. Hajos M, Hajos-Korcsok E, Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 1999, 126:1741-50.
29. Loughlin SE, Foote SL, Grzanna R. Efferent projections of nucleus locus coeruleus: Morphologic subpopulations have different efferent targets. Neuroscience 1986, 18:307-19.
30. Loughlin SE, Foote SL, Bloom FE. Efferent projections of nucleus locus coeruleus: Topographic organization of cells of origin demonstrated by three-dimensional reconstruction. Neuroscience 1986, 18:291-306.
31. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005, 315:265-72.
32. Korotkova TM, Ponomarenko AA, Brown RE, Haas HL. Functional diversity of ventral midbrain dopamine and GABAergic neurons. Mol Neurobiol 2004, 29:243-59.
33. Margolis EB, Mitchell JM, Ishikawa J, Hjelmstad GO, Fields HL. Midbrain dopamine neurons: Projection target determines action potential duration and dopamine D (2) receptor inhibition. J Neurosci 2008, 28:8908-13.
34. Di CG. Nucleus accumbens shell and core dopamine: Differential role in behavior and addiction. Behav Brain Res 2002, 137:75-114.
35. Borsini F, Cesana R. Mechanism of action of flibanserin in the learned helplessness paradigm in rats. Eur J Pharmacol 2001, 433:81-9.
36. Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007, 59:360-417.